Jeffrey Del Carmen is Chief Commercial Officer of CATALYST PHARMACEUTICALS, INC.. Currently has a direct ownership of 12,369 shares of CPRX, which is worth approximately $270,757. The most recent transaction as insider was on Aug 09, 2024, when has been sold 36,058 shares (Common Stock, par value $0.001 per share) at a price of $18.43 per share, resulting in proceeds of $664,548. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 12.4K
32.88% 3M change
9.04% 12M change
Total Value Held $270,757

Jeffrey Del Carmen Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 09 2024
SELL
Open market or private sale
$664,548 $18.43 p/Share
36,058 Reduced 74.46%
12,369 Common Stock, par valu...
Aug 09 2024
BUY
Exercise of conversion of derivative security
$85,800 $2.86 p/Share
30,000 Added 41.45%
42,369 Common Stock, par valu...
Jun 07 2024
SELL
Open market or private sale
$121,183 $16.07 p/Share
7,541 Reduced 29.04%
18,427 Common Stock, par valu...
Feb 15 2024
SELL
Payment of exercise price or tax liability
-
3,125 Reduced 10.74%
25,968 Common Stock, par valu...
Feb 15 2024
BUY
Exercise of conversion of derivative security
-
10,667 Added 26.83%
29,093 Common Stock, par valu...
Dec 27 2023
SELL
Payment of exercise price or tax liability
-
3,839 Reduced 17.24%
18,426 Common Stock, par valu...
Dec 27 2023
BUY
Exercise of conversion of derivative security
-
8,666 Added 28.02%
22,265 Common Stock, par valu...
Jun 27 2023
SELL
Payment of exercise price or tax liability
-
3,942 Reduced 22.47%
13,599 Common Stock, par valu...
Jun 27 2023
BUY
Exercise of conversion of derivative security
-
10,000 Added 36.31%
17,541 Common Stock, par valu...
Mar 29 2023
SELL
Open market or private sale
$668,000 $16.7 p/Share
40,000 Reduced 84.14%
7,541 Common Stock, par valu...
Mar 29 2023
BUY
Exercise of conversion of derivative security
$129,200 $3.23 p/Share
40,000 Added 60.1%
26,558 Common Stock, par valu...
Feb 15 2023
SELL
Payment of exercise price or tax liability
-
3,125 Reduced 29.3%
7,541 Common Stock, par valu...
Feb 15 2023
BUY
Exercise of conversion of derivative security
-
10,666 Added 50.0%
10,666 Common Stock, par valu...
Nov 11 2022
SELL
Open market or private sale
$2,203,419 $15.85 p/Share
139,017 Reduced 100.0%
0 Common Stock, par valu...
Nov 11 2022
BUY
Exercise of conversion of derivative security
$354,493 $2.55 p/Share
139,017 Added 87.97%
19,017 Common Stock, par valu...
Aug 19 2022
BUY
Open market or private sale
$198,667 $14.05 p/Share
14,140 Added 100.0%
0 Common Stock, par valu...
Jun 28 2022
SELL
Payment of exercise price or tax liability
-
2,930 Reduced 17.16%
14,140 Common Stock, par valu...
Jun 28 2022
BUY
Exercise of conversion of derivative security
-
10,000 Added 36.94%
17,070 Common Stock, par valu...
Jun 24 2021
SELL
Payment of exercise price or tax liability
-
2,930 Reduced 29.3%
7,070 Common Stock, par valu...
Jun 24 2021
BUY
Exercise of conversion of derivative security
-
10,000 Added 50.0%
10,000 Common Stock, par valu...
JDC

Jeffrey Del Carmen

Chief Commercial Officer
Coral Gables, FL

Track Institutional and Insider Activities on CPRX

Follow CATALYST PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CPRX shares.

Notify only if

Insider Trading

Get notified when an Catalyst Pharmaceuticals, Inc. insider buys or sells CPRX shares.

Notify only if

News

Receive news related to CATALYST PHARMACEUTICALS, INC.

Track Activities on CPRX